HealthCare Global Enterprises Limited has announced a comprehensive investment plan worth ₹253.66 crore following board approvals on March 30, 2026. The healthcare company's board has sanctioned ₹98 crore for investment in HCG NCHRI LLP, its wholly owned subsidiary, and up to ₹155.66 crore for acquiring an additional 34% stake in Vizag Hospital and Cancer Research Centre Private Limited.

Board Approved Investment Breakdown

The company's board has structured the investment across two key subsidiaries to strengthen operations and expand strategic holdings.

HCG NCHRI LLP Investment Details

The ₹98 crore investment in HCG NCHRI LLP will enable pre-payment and repayment of outstanding borrowings. The subsidiary operates a 74-bedded cancer care centre in Nagpur and reported strong financial performance with revenue from operations of ₹89.80 crore and profit after tax of ₹17.02 crore for the financial year ended March 31, 2025.

Vizag Hospital Acquisition Strategy

The board's approval enables Healthcare Global Enterprises to acquire an additional 34% stake in Vizag Hospital, bringing total ownership to 85%. This acquisition follows the Share Purchase Agreement dated June 28, 2024, as amended through agreements executed on October 01, 2024 and March 29, 2026.

Financial Performance Overview

Vizag Hospital demonstrated solid operational performance with revenue from operations of ₹110.14 crore and profit after tax of ₹18.79 crore for the financial year ended March 31, 2025. The entity was incorporated on March 05, 1986, and operates from Visakhapatnam, Andhra Pradesh.

Rights Issue Alignment

Both investments align with the stated objects of the rights issue approved by the company on February 24, 2026. The rights issue allocated approximately ₹98 crore for the HCG NCHRI LLP investment and ₹154.04 crore for the Vizag Hospital acquisition, subject to adjustments or incremental payments as per agreement terms.

Strategic Implications

The board meeting, which commenced at 1:45 p.m. and concluded at 3:40 p.m. IST, reflects the company's commitment to strengthening its subsidiary network while maintaining focus on cancer care services. Both investments are expected to be completed in Q1 FY27, with no governmental or regulatory approvals required for either transaction.

Healthcare Global Enterprises Limited has completed the winding up of its wholly owned indirect subsidiary Healthcare Global (Tanzania) Private Limited, marking the end of its corporate presence in Tanzania. The company received formal notification of the winding up on March 26, 2026, though the effective date of closure was March 02, 2026.

Subsidiary Details and Operations

Healthcare Global (Tanzania) Private Limited was a non-operating entity incorporated in Tanzania. The subsidiary had remained inactive throughout its existence, contributing nothing to the parent company's financial performance.

Financial Impact Assessment

The closure of HCG Tanzania will have no material impact on HealthCare Global Enterprises' financial position. During the last financial year, the subsidiary made no contribution to the parent company's operations or financial metrics.

Regulatory Compliance

The announcement was made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has fulfilled all disclosure requirements as mandated by SEBI circulars SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

The winding up process did not involve any sale transactions, related party dealings, or schemes of arrangement. As a non-operational indirect subsidiary, the closure represents a routine corporate housekeeping measure rather than a strategic business decision with operational implications.